Quick Answer
Syndax Pharmaceuticals Inc reported R&D Expense of $258.78 million for fiscal year 2025.
Syndax Pharmaceuticals Inc R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $258.78M | +7.1% |
| 2024 | $241.65M | +48.2% |
| 2023 | $163.03M | +37.6% |
| 2022 | $118.50M | +34.3% |
| 2021 | $88.25M | +75.0% |
| 2020 | $50.44M | +17.3% |
| 2019 | $42.99M | -28.5% |
| 2018 | $60.11M | +24.7% |
| 2017 | $48.20M | +52.2% |
| 2016 | $31.66M | +231.6% |
| 2015 | $9.55M | -6.2% |
| 2014 | $10.18M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $56.28M | -20.7% | -9.6% |
| June 30, 2025 | $62.23M | +27.9% | +1.0% |
| March 31, 2025 | $61.64M | +9.1% | -13.2% |
| September 30, 2024 | $70.97M | +81.6% | +45.9% |
| June 30, 2024 | $48.66M | +40.0% | -13.9% |
| March 31, 2024 | $56.49M | +65.9% | +44.5% |
| September 30, 2023 | $39.09M | +45.3% | +12.4% |
| June 30, 2023 | $34.76M | +16.9% | +2.1% |
- Syndax Pharmaceuticals Inc showed an increase of +7.1% in R&D Expense compared to the prior fiscal year.
- Over the 2014–2025 period, Syndax Pharmaceuticals Inc’s r&d expense has grown by 2443.3% (from $10.18 million to $258.78 million).
- The most recent figure is from Syndax Pharmaceuticals Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: